Sakar Healthcare Limited has informed the Exchange regarding Board meeting held on May 15, 2025.
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sakar Healthcare's board approved its audited FY25 results (standalone and consolidated, both identical figures). Revenue from operations rose about 15.8% to Rs 17,758.47 lakh versus Rs 15,335.17 lakh in FY24. Profit after tax jumped roughly 50% to Rs 1,750.20 lakh (FY24: Rs 1,167.09 lakh), with EPS climbing to Rs 7.97 from Rs 5.64. Q4 FY25 was particularly strong, with PAT of Rs 576.11 lakh (up ~85% year-on-year) on revenue of Rs 5,024.18 lakh. Statutory auditor J.S. Shah & Co. issued an unmodified (clean) opinion, and the company confirmed no deviation in the use of Rs 5.76 crore raised via preferential warrant conversion in December 2024.
Strong profit growth driven by margin expansion is positive for shareholders; revenue growth is solid but below 20%, while PAT growth well exceeds 25%. Clean audit opinion and no loan defaults support near-term investor confidence.